logo
AAT Bioquest

Psoralen MOP Succinimidyl Ester

Product Image
Product Image
Gallery Image 1
Ordering information
Price
Catalog Number
Unit Size
Quantity
Add to cart
Additional ordering information
Telephone1-800-990-8053
Fax1-800-609-2943
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
ShippingStandard overnight for United States, inquire for international
Request quotation
Physical properties
Molecular weight385.33
SolventDMSO
Storage, safety and handling
H-phraseH303, H313, H333
Hazard symbolXN
Intended useResearch Use Only (RUO)
R-phraseR20, R21, R22
StorageFreeze (< -15 °C); Minimize light exposure

OverviewpdfSDSpdfProtocol


Molecular weight
385.33
Psoralens and their derivatives (such as 8-MOP and 4,5’8-TMP) are well known to have unique crosslinking features to DNA. However, psoralen monomers do not have sequence-specific crosslinking ability with a target DNA. Nakao et al found that 5-MOP more effectively crosslinks DNA compared to the well-known 8-MOP (https://doi.org/10.1002/cbic.202200789). Psoralen MOP Succinimidyl Ester is a 5-MOP derivative. It is an excellent building block for preparing MOP-labeled oligos from the readily available amino-modified oligos. The 5-MOP-conjugated oligonucleotides can be used for sequence-specific crosslinking with a target DNA, thus enabling the application of psoralen-conjugated molecules in gene transcription inhibition, gene knockout, and other genomic applications. Psoralen MOP Succinimidyl Ester may also be used for preparing site-specific DNA/RNA probes via the conjugations with amino-containing biomolecules such as antibodies.

Calculators


Common stock solution preparation

Table 1. Volume of DMSO needed to reconstitute specific mass of Psoralen MOP Succinimidyl Ester to given concentration. Note that volume is only for preparing stock solution. Refer to sample experimental protocol for appropriate experimental/physiological buffers.

0.1 mg0.5 mg1 mg5 mg10 mg
1 mM259.518 µL1.298 mL2.595 mL12.976 mL25.952 mL
5 mM51.904 µL259.518 µL519.036 µL2.595 mL5.19 mL
10 mM25.952 µL129.759 µL259.518 µL1.298 mL2.595 mL

Molarity calculator

Enter any two values (mass, volume, concentration) to calculate the third.

Mass (Calculate)Molecular weightVolume (Calculate)Concentration (Calculate)Moles
/=x=

Images


References


View all 49 references: Citation Explorer
Protective effects of 8-MOP on blood-brain barrier via the Nrf-2/HO-1 pathway in mice model of cerebral infarction.
Authors: Liu, C and Zhong, L and Tian, X-L and Han, Y-C
Journal: European review for medical and pharmacological sciences (2018): 4278-4287
The anti-metastatic effect of 8-MOP on hepatocellular carcinoma is potentiated by the down-regulation of bHLH transcription factor DEC1.
Authors: Xiong, Jing and Yang, Huan and Luo, Wenjing and Shan, Enfang and Liu, Jie and Zhang, Feng and Xi, Tao and Yang, Jian
Journal: Pharmacological research (2016): 121-33
Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity.
Authors: Deeni, Yusuf Y and Ibbotson, Sally H and Woods, Julie A and Wolf, C Roland and Smith, Gillian
Journal: PloS one (2013): e75494
Establishment of mus skin photo-damage model by 8-MOP plus UVA irradiation.
Authors: Liang, Hong and Li, Jiawen and Zhang, Li
Journal: Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen (2007): 742-4
Antigenotoxic effects of three essential oils in diploid yeast (Saccharomyces cerevisiae) after treatments with UVC radiation, 8-MOP plus UVA and MMS.
Authors: Bakkali, F and Averbeck, S and Averbeck, D and Zhiri, A and Baudoux, D and Idaomar, M
Journal: Mutation research (2006): 27-38
Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses.
Authors: Engin, Burhan and Oguz, Oya
Journal: International journal of dermatology (2005): 337-9
Analysis of p53 tumor suppressor gene, H-ras protooncogene and proliferating cell nuclear antigen (PCNA) in squamous cell carcinomas of HRA/Skh mice following exposure to 8-methoxypsoralen (8-MOP) and UVA radiation (PUVA therapy).
Authors: Lambertini, Luca and Surin, Kezia and Ton, Thai-Vu T and Clayton, Natasha and Dunnick, June K and Kim, Yongbaek and Hong, Hue-Hua L and Devereux, Theodora R and Sills, Robert C
Journal: Toxicologic pathology (2005): 292-9
Effects of 5-methoxypsoralen (5-MOP) on arylamine N-acetyltransferase activity in the stomach and colon of rats and human stomach and colon tumor cell lines.
Authors: Lee, Yi-Min and Wu, Tai-Hsien
Journal: In vivo (Athens, Greece) (2005): 1061-9
UVA activated 8-MOP and chlorpromazine inhibit release of TNF-alpha by post-transcriptional regulation.
Authors: Wolnicka-Glubisz, Agnieszka and Sarna, Tadeusz and Klosner, Gabriele and Knobler, Robert and Trautinger, Franz
Journal: Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society (2004): 334-6
Effect of 5-methoxypsoralen (5-MOP) on cell apoptosis and cell cycle in human hepatocellular carcinoma cell line.
Authors: Lee, Y M and Wu, T H and Chen, S F and Chung, J G
Journal: Toxicology in vitro : an international journal published in association with BIBRA (2003): 279-87